Knockdown of USP7 alleviates atherosclerosis in ApoE-deficient mice by regulating EZH2 expression
- PMID: 39310812
- PMCID: PMC11416069
- DOI: 10.1515/biol-2022-0929
Knockdown of USP7 alleviates atherosclerosis in ApoE-deficient mice by regulating EZH2 expression
Abstract
Atherosclerosis (AS) is a chronic vascular disease associated with lipid accumulation. Understanding the molecular mechanisms of AS is essential. Ubiquitin-specific protease 7 (USP7) is a deubiquitination enzyme involved in various cellular processes, including lipid metabolism. In this study, we aimed to elucidate the role of USP7 in AS progression and its underlying mechanism using ApoE-deficient mice. We found that USP7 ablation improved the morphological characteristics of AS in these mice. USP7 knockdown reduced inflammation, evidenced by decreases in inflammatory markers IL-6, TNF-α, and IL-1β by 35, 40, and 38%, respectively (p < 0.01). Additionally, USP7 depletion reduced oxidative stress, indicated by a 30% reduction in malondialdehyde levels and increases in superoxide dismutase and glutathione peroxidase levels by 25 and 28%, respectively (p < 0.01). Moreover, USP7 knockdown blocked lipid accumulation in aortic tissue cells. Mechanistically, USP7 knockdown inhibited enhancer of Zeste Homolog 2 (EZH2) expression, thereby suppressing AS progression. In conclusion, USP7 depletion alleviated AS progression in ApoE-deficient mice by targeting EZH2 expression. USP7 may serve as a therapeutic target for AS.
Keywords: EZH2; atherosclerosis; inflammation; oxidative stress; ubiquitin-specific protease 7.
© 2024 the author(s), published by De Gruyter.
Conflict of interest statement
Conflict of interest: Authors state no conflict of interest.
Figures





Similar articles
-
USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells.Genet Mol Biol. 2020 May 20;43(2):e20190338. doi: 10.1590/1678-4685-GMB-2019-0338. eCollection 2020. Genet Mol Biol. 2020. PMID: 32453339 Free PMC article.
-
USP7 stabilizes EZH2 and enhances cancer malignant progression.Am J Cancer Res. 2020 Jan 1;10(1):299-313. eCollection 2020. Am J Cancer Res. 2020. PMID: 32064169 Free PMC article.
-
Structural Basis of the Interaction Between Ubiquitin Specific Protease 7 and Enhancer of Zeste Homolog 2.J Mol Biol. 2020 Feb 14;432(4):897-912. doi: 10.1016/j.jmb.2019.12.026. Epub 2019 Dec 20. J Mol Biol. 2020. PMID: 31866294
-
USP7 as an emerging therapeutic target: A key regulator of protein homeostasis.Int J Biol Macromol. 2024 Apr;263(Pt 1):130309. doi: 10.1016/j.ijbiomac.2024.130309. Epub 2024 Feb 19. Int J Biol Macromol. 2024. PMID: 38382779 Review.
-
The Role and Mechanism of Deubiquitinase USP7 in Tumor-Associated Inflammation.Biomedicines. 2024 Nov 29;12(12):2734. doi: 10.3390/biomedicines12122734. Biomedicines. 2024. PMID: 39767641 Free PMC article. Review.
Cited by
-
USP7 Stabilizes USF1 to Aggravate ox-LDL-Induced Endothelial Injury Through the MYD88/NF-κB Pathway in Atherosclerosis.Appl Biochem Biotechnol. 2025 Jul 18. doi: 10.1007/s12010-025-05312-2. Online ahead of print. Appl Biochem Biotechnol. 2025. PMID: 40679551
References
-
- Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(8 Suppl):C7–12. - PubMed
-
- Choi HY, Iatan I, Ruel I, Brown L, Hales L, Choi S, et al. Docetaxel as a model compound to promote HDL (high-density lipoprotein) biogenesis and reduce atherosclerosis. Arterioscler Thromb Vasc Biol. 2023;43(5):609–17. - PubMed
-
- Zeng J, Zhang J, Sun Y, Wang J, Ren C, Banerjee S, et al. Targeting EZH2 for cancer therapy: from current progress to novel strategies. Eur J Med Chem. 2022;238:114419. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous